大剂量阿糖胞苷治疗儿童急性髓性白血病的发展现状  

Current situation of high-dose cytarabine in treatment of children with acute myeloid leukemia

作　　者：胡静雯[1] 于雅莲[1] 黄家珍[1] 

机构地区：[1]中国医科大学,七年制临床医学辽宁沈阳110004

出　　处：《中国医药导报》2011年第22期8-9,共2页China Medical Herald

摘　　要：阿糖胞苷作为治疗儿童急性髓性白血病的化学治疗药物的主要药物之一,其作用机制得到深入研究。近年来,随着大剂量阿糖胞苷在急性髓性白血病化疗过程中的广泛应用,其高浓度依赖性毒副作用日益严重。如何选用最佳剂量及疗程是大剂量阿糖胞苷治疗儿童急性髓性白血病的关键问题。本文将对大剂量阿糖胞苷治疗儿童急性髓性白血病的发展现状作一综述。Cytarabine is used as one of the main durgs to treat the acute myeloid leukemia and its mechanism of action has been investigated further.The superiority of high-dose cytarabine has been thought highly in the recent years,but the adverse effects can not be avoided.This paper will review the current situation of high-dose cytarabine in treatment of children with acute myeloid leukemia.

关 键 词：急性髓性白血病 儿童 大剂量阿糖胞苷 

分 类 号：R733.71[医药卫生—肿瘤]